Selected research
Industry Research
Cefadroxil Industry Research Report 2026
Market perspective
The global Cefadroxil market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Cefadroxil is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Cefadroxil is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Cefadroxil is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Cefadroxil include Huafangpharm, Dongying Pharmaceutical, Qilu Antibiotics, Fukang, Union Chempharma, SALUBRIS, NCPC, Lupin Pharmaceuticals and LKPC, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Cefadroxil market in terms of revenue (US$ million) and, where applicable, sales volume (tons), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/tons) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Cefadroxil Market by Company
Huafangpharm
Dongying Pharmaceutical
Qilu Antibiotics
Fukang
Union Chempharma
SALUBRIS
NCPC
Lupin Pharmaceuticals
LKPC
LIVZON
HPGC
CSPC
Covalent Laboratories
Alkem
Cefadroxil Segment by Type
USP
EP
Cefadroxil Segment by Application
Tablet
Capsule
Cefadroxil Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cefadroxil market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Cefadroxil and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cefadroxil.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Cefadroxil manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Cefadroxil by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Cefadroxil in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- USP
- EP
Applications
- Tablet
- Capsule
Companies covered
- Huafangpharm
- Dongying Pharmaceutical
- Qilu Antibiotics
- Fukang
- Union Chempharma
- SALUBRIS
- NCPC
- Lupin Pharmaceuticals
- LKPC
- LIVZON
- HPGC
- CSPC
- Covalent Laboratories
- Alkem
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Cefadroxil Market Size (2021-2032)
- 2.2.2 Global Cefadroxil Sales (2021-2032)
- 2.2.3 Global Cefadroxil Market Average Price (2021-2032)
- 2.3 Cefadroxil by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 USP
- 2.3.3 EP
- 2.4 Cefadroxil by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Tablet
- 2.4.3 Capsule
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Cefadroxil Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Cefadroxil Sales (tons) of Manufacturers (2021-2026)
- 3.3 Global Cefadroxil Revenue of Manufacturers (2021-2026)
- 3.4 Global Cefadroxil Average Price by Manufacturers (2021-2026)
- 3.5 Global Cefadroxil Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Cefadroxil, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Cefadroxil, Product Type & Application
- 3.8 Global Manufacturers of Cefadroxil, Established Date
- 3.9 Global Cefadroxil Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Huafangpharm
- 4.1.1 Huafangpharm Company Information
- 4.1.2 Huafangpharm Business Overview
- 4.1.3 Huafangpharm Cefadroxil Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Huafangpharm Cefadroxil Product Portfolio
- 4.1.5 Huafangpharm Recent Developments
- 4.2 Dongying Pharmaceutical
- 4.2.1 Dongying Pharmaceutical Company Information
- 4.2.2 Dongying Pharmaceutical Business Overview
- 4.2.3 Dongying Pharmaceutical Cefadroxil Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Dongying Pharmaceutical Cefadroxil Product Portfolio
- 4.2.5 Dongying Pharmaceutical Recent Developments
- 4.3 Qilu Antibiotics
- 4.3.1 Qilu Antibiotics Company Information
- 4.3.2 Qilu Antibiotics Business Overview
- 4.3.3 Qilu Antibiotics Cefadroxil Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Qilu Antibiotics Cefadroxil Product Portfolio
- 4.3.5 Qilu Antibiotics Recent Developments
- 4.4 Fukang
- 4.4.1 Fukang Company Information
- 4.4.2 Fukang Business Overview
- 4.4.3 Fukang Cefadroxil Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Fukang Cefadroxil Product Portfolio
- 4.4.5 Fukang Recent Developments
- 4.5 Union Chempharma
- 4.5.1 Union Chempharma Company Information
- 4.5.2 Union Chempharma Business Overview
- 4.5.3 Union Chempharma Cefadroxil Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Union Chempharma Cefadroxil Product Portfolio
- 4.5.5 Union Chempharma Recent Developments
- 4.6 SALUBRIS
- 4.6.1 SALUBRIS Company Information
- 4.6.2 SALUBRIS Business Overview
- 4.6.3 SALUBRIS Cefadroxil Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 SALUBRIS Cefadroxil Product Portfolio
- 4.6.5 SALUBRIS Recent Developments
- 4.7 NCPC
- 4.7.1 NCPC Company Information
- 4.7.2 NCPC Business Overview
- 4.7.3 NCPC Cefadroxil Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 NCPC Cefadroxil Product Portfolio
- 4.7.5 NCPC Recent Developments
- 4.8 Lupin Pharmaceuticals
- 4.8.1 Lupin Pharmaceuticals Company Information
- 4.8.2 Lupin Pharmaceuticals Business Overview
- 4.8.3 Lupin Pharmaceuticals Cefadroxil Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Lupin Pharmaceuticals Cefadroxil Product Portfolio
- 4.8.5 Lupin Pharmaceuticals Recent Developments
- 4.9 LKPC
- 4.9.1 LKPC Company Information
- 4.9.2 LKPC Business Overview
- 4.9.3 LKPC Cefadroxil Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 LKPC Cefadroxil Product Portfolio
- 4.9.5 LKPC Recent Developments
- 4.10 LIVZON
- 4.10.1 LIVZON Company Information
- 4.10.2 LIVZON Business Overview
- 4.10.3 LIVZON Cefadroxil Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 LIVZON Cefadroxil Product Portfolio
- 4.10.5 LIVZON Recent Developments
- 4.11 HPGC
- 4.11.1 HPGC Company Information
- 4.11.2 HPGC Business Overview
- 4.11.3 HPGC Cefadroxil Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 HPGC Cefadroxil Product Portfolio
- 4.11.5 HPGC Recent Developments
- 4.12 CSPC
- 4.12.1 CSPC Company Information
- 4.12.2 CSPC Business Overview
- 4.12.3 CSPC Cefadroxil Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 CSPC Cefadroxil Product Portfolio
- 4.12.5 CSPC Recent Developments
- 4.13 Covalent Laboratories
- 4.13.1 Covalent Laboratories Company Information
- 4.13.2 Covalent Laboratories Business Overview
- 4.13.3 Covalent Laboratories Cefadroxil Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Covalent Laboratories Cefadroxil Product Portfolio
- 4.13.5 Covalent Laboratories Recent Developments
- 4.14 Alkem
- 4.14.1 Alkem Company Information
- 4.14.2 Alkem Business Overview
- 4.14.3 Alkem Cefadroxil Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Alkem Cefadroxil Product Portfolio
- 4.14.5 Alkem Recent Developments
5 Global Cefadroxil Market Scenario by Region
- 5.1 Global Cefadroxil Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Cefadroxil Sales by Region: 2021-2032
- 5.2.1 Global Cefadroxil Sales by Region: 2021-2026
- 5.2.2 Global Cefadroxil Sales by Region: 2027-2032
- 5.3 Global Cefadroxil Revenue by Region: 2021-2032
- 5.3.1 Global Cefadroxil Revenue by Region: 2021-2026
- 5.3.2 Global Cefadroxil Revenue by Region: 2027-2032
- 5.4 North America Cefadroxil Market Facts & Figures by Country
- 5.4.1 North America Cefadroxil Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Cefadroxil Sales by Country (2021-2032)
- 5.4.3 North America Cefadroxil Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Cefadroxil Market Facts & Figures by Country
- 5.5.1 Europe Cefadroxil Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Cefadroxil Sales by Country (2021-2032)
- 5.5.3 Europe Cefadroxil Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Cefadroxil Market Facts & Figures by Country
- 5.6.1 Asia Pacific Cefadroxil Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Cefadroxil Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Cefadroxil Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Cefadroxil Market Facts & Figures by Country
- 5.7.1 South America Cefadroxil Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Cefadroxil Sales by Country (2021-2032)
- 5.7.3 South America Cefadroxil Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Cefadroxil Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Cefadroxil Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Cefadroxil Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Cefadroxil Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Cefadroxil Sales by Type (2021-2032)
- 6.1.1 Global Cefadroxil Sales by Type (2021-2032) & (tons)
- 6.1.2 Global Cefadroxil Sales Market Share by Type (2021-2032)
- 6.2 Global Cefadroxil Revenue by Type (2021-2032)
- 6.2.1 Global Cefadroxil Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Cefadroxil Revenue Market Share by Type (2021-2032)
- 6.3 Global Cefadroxil Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Cefadroxil Sales by Application (2021-2032)
- 7.1.1 Global Cefadroxil Sales by Application (2021-2032) & (tons)
- 7.1.2 Global Cefadroxil Sales Market Share by Application (2021-2032)
- 7.2 Global Cefadroxil Revenue by Application (2021-2032)
- 7.2.1 Global Cefadroxil Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Cefadroxil Revenue Market Share by Application (2021-2032)
- 7.3 Global Cefadroxil Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Cefadroxil Value Chain Analysis
- 8.1.1 Cefadroxil Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Cefadroxil Production Mode & Process
- 8.2 Cefadroxil Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Cefadroxil Distributors
- 8.2.3 Cefadroxil Customers
9 Global Cefadroxil Analyzing Market Dynamics
- 9.1 Cefadroxil Industry Trends
- 9.2 Cefadroxil Industry Drivers
- 9.3 Cefadroxil Industry Opportunities and Challenges
- 9.4 Cefadroxil Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst